A woman on daclizumab developed thrombotic microangiopathy secondary to cyclosporine after a living-unrelated kidney transplant. Despite cyclosporine discontinuation, hemolysis persisted. The second dose of daclizumab was postponed 24 h, and after a maximum of two sessions of plasmapheresis (to avoid further modifications in daclizumab schedule) with plasma exchange, daclizumab was administered. Plasma infusions were prescribed until D-dimer and fibrinogen-degradation products normalized; thereafter, FK-506 was started without recurrence of the hemolytic picture and renal function restored. This observation suggests that in patients on daclizumab who develop thrombotic microangiopathy secondary to immunosuppressants, if discontinuation of the offending drug is unsuccessful, plasmapheresis with plasma exchange can be performed when the lowest levels of daclizumab exist, followed by daclizumab infusion. Plasma prescription must be continued thereafter until D-dimer and figrinogen-degradation products normalize. However, if hemolysis persists when daclizumab levels are high, plasma infusions are useful and plasmapheresis avoided. FK-506 administration did not result in recurrence of hemolysis during daclizumab induction.

Keywords:
Kidney transplantation, Thrombotic microangiopathy, Cyclosporine, Daclizumab, Plasma infusions, Plasmapheresis, FK-506, D-dimer, Fibrinogen-degradation products, Panel-reactive antibodies
1.
Mihatsch M, Ryffel B, Gudat F, Thiel G: Cyclosporine nephropathy; in Tisher CC, Brenner BM (eds): Renal Pathology with Clinical and Functional Correlations. Philadelphia, Lippincott, 1989, p 1570.
2.
Zarifian A, Meleg-Smith S, O’Donovan R, et al: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999;55:2457.
3.
Butkus D, Herrera G, Raju S: Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation. Transplantation 1992;54:159.
4.
Franz M, Regele H, Schmoldienst S, Stummovoll H, Horl W, Pehanka E: Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients. Advantage of FK-506 therapy? Transplantation 1998;66:1258.
5.
Randhawa P, Tsamandas A, Magnone M, et al: Microvascular changes in renal allografts associated with FK-506 (tacrolimus) therapy. Am J Surg Pathol 1996;20:306.
6.
Mach-Pascual S, Samii K, Beris P: Microangiopathic hemolytic anemia complicating FK-506 (tacrolimus) therapy. Am J Hematol 1996;52:310.
7.
Zent R, Katz A, Quaggin S, et al: Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol 1997;47:181.
8.
Pollack M, Trimarchi H, Riley D, et al: Shared cadaver donor-husband HLA class I mismatches as a risk factor for renal graft rejection in previously pregnant women. Hum Immunol 1999;60:1150.
9.
Trimarchi H, Truong L, Brennan S, et al: FK-506-associated thrombotic microangiopathy. Report of two cases and review of the literature. Transplantation 1999;67:539.
10.
Kaplan B, Meyers K, Schulman S: The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1999;9:1126.
11.
Vincenti F, Lantz M, Birnmaum J, et al: A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997;63:33.
12.
Van Geet C, Proesmans W, Arnout J, et al: Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Kidney Int 1998;54:1324.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.